NCT00396682

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Hannover Medical School · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.

Conditions

• Advanced HCC

Interventions

Type	Name	Description
DRUG	Cyclophosphamide	150 - 250 - 350 mg

Timeline

• Start date: 2007-02-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2006-11-07
• Last updated: 2009-02-04

Locations

1 site across 1 country: Germany